BACKGROUND To assess whether the addition of cisplatin (100 mg/m2 administered
intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m2 on Day 1], doxorubicin [45 …

Purpose: Treatment of advanced Non small cell lung cancer (NSCLC) often produces dismal
results. Combination of available treatment modalities has reportedly improved the outcome …

RESULTS Twenty-nine patients (21 male; eight female) were treated with etoposide and
cisplatin as described. Three patients died early and were inevaluable for response. Two of …

Previously untreated extensive small-cell lung cancer (SCLC) patients with performance
status 0–2 were treated with etoposide 200 mg/m 2/day on days 1–3 and carboplatin doses …

PURPOSE: The combination of cisplatin, etoposide, and paclitaxel was studied in patients
with extensive small-cell lung cancer in a phase I component followed by a phase II trial to …

7057 Background: Amrubicin achieved the high response rate of 78.8% and median survival
of 11.3 months in patients with previously untreated extensive disease SCLC. The …

The combination of carboplatin and etoposide was evaluated in 61 previously untreated
patients with extensive small cell lung cancer. Treatment was given at four-week intervals …

Whithin an original consecutive series of 94 patients, 36 eligible patients with small cell lung
carcinoma were treated with high-dose cyclophosphamide 7 g/m 2 after conventional …

Small cell lung cancers, comprising approximately 20% of lung cancers, are rapidly growing
and disseminating carcinomas which are initially chemosensitive but acquire drug …

The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations
along with thoracic irradiation were prospectively assessed in patients with small cell lung …